Targeted Oncology· @TargetedOnc · X·· 15 小时前评分70
正文 · 原文
A question for the INTerpath-001 panel:
With neoadjuvant nivo/ipi already transforming melanoma care, where will personalized mRNA vaccines fit?
Should future studies integrate vaccination into neoadjuvant strategies rather than simply intensifying adjuvant therapy?
#ESMO26
118 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Targeted Oncology · x.com